Dexrazoxane Hydrochloride is the hydrochloride salt of a bisdioxopiperazine with iron-chelating, chemoprotective, cardioprotective, and antineoplastic activities. After hydrolysis to an active form that is similar to ethylenediaminetetraacetic acid (EDTA), dexrazoxane chelates iron, limiting the formation of free radical-generating anthracycline-iron complexes, which may minimize anthracycline-iron complex-mediated oxidative damage to cardiac and soft tissues. This agent also inhibits the catalytic activity of topoisomerase II, which may result in tumor cell growth inhibition.
Dexrazoxane is a bisdioxopiperazine with iron-chelating, chemoprotective, cardioprotective, and antineoplastic activities. After hydrolysis to an active form that is similar to ethylenediaminetetraacetic acid (EDTA), dexrazoxane chelates iron, limiting the formation of free radical-generating anthracycline-iron complexes, which may minimize anthracycline-iron complex-mediated oxidative damage to cardiac and soft tissues. This agent also inhibits the catalytic activity of topoisomerase II, which may result in tumor cell growth inhibition.
Dexrazoxane is a cytoprotective drug used to prevent and improve cardiomyopathy associated with doxorubicin treatment for metastatic breast cancer. An antimitotic agent with immunosuppressive properties. Dexrazoxane, the (+)-enantiomorph of razoxane, provides cardioprotection against anthracycline toxicity. It appears to inhibit the formation of a toxic iron-anthracycline complex. [PubChem] The Food and Drug Administration has designated dexrazoxane as an orphan drug for use in the prevention or reduction in the incidence and severity of anthracycline-induced cardiomyopathy.
Mechanism of Action
The mechanism by which dexrazoxane exerts its cardioprotective activity is not fully understood. Dexrazoxane is a cyclic derivative of EDTA that readily penetrates cell membranes. Results of laboratory studies suggest that dexrazoxane (a prodrug) is converted intracellularly to a ring-opened bidentate chelating agent that chelates to free iron and interferes with iron-mediated free radical generation thought to be responsible, in part, for anthracycline-induced cardiomyopathy. It should be noted that dexrazoxane may also be protected through its inhibitory effect on topoisomerase II.
or
The mechanism of action of dexrazoxane’s cardioprotective activity is not fully understood. Dexrazoxane is a cyclic derivative of ethylenediamine tetra-acetic acid (EDTA) that readily penetrates cell membranes. Laboratory studies suggest that dexrazoxane is converted intracellularly to a ring-opened chelating agent that interferes with iron-mediated free radical generation thought to be responsible, in part, for anthracycline-induced cardiomyopathy.
Dexrazoxane is a cardioprotective agent for use in conjunction with doxorubicin indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose. Patients receiving anthracycline-derivative antineoplastic agents may experience three types of cardiotoxicity: acute transient type; chronic, subacute type (related to cumulative dose and has a more indolent onset later on); and a late-onset type that manifests years after therapy, mainly in patients that have been exposed to the drug as a child. Although the exact mechanism of anthracycline-induced cardiotoxicity is not known, it has been shown to exert a variety of actions that may result in the development of cardiotoxicity. In animals, anthracyclines cause a selective inhibition of cardiac muscle gene expression for α-actin, troponin, myosin light-chain 2, and the M isoform of creatine kinase. This may lead to myofibrillar loss associated with anthracycline-induced cardiotoxicity. Anthracyclines may also cause myocyte damage via calcium overload, altered myocardial adrenergic function, the release of vasoactive amines, and proinflammatory cytokines. Furthermore, it has been suggested that the main cause of anthracycline-induced cardiotoxicity is associated with free-radical damage to DNA. The drugs intercalate DNA, chelate metal ions to produce drug-metal complexes, and generate superoxide radicals via oxidation-reduction reactions. Anthracyclines also contain a quinone structure that can undergo reduction via NADPH-dependent reactions to produce a semiquinone free radical that initiates a cascade of superoxide and hydroxide radical generation. Chelation of metal ions, particularly iron, by anthracyclines results in an anthracycline-metal complex that catalyzes the generation of reactive oxygen free radicals. This complex is a powerful oxidant that can initiate lipid peroxidation in the absence of oxygen free radicals. The toxicity induced by anthracyclines may be exacerbated in cardiac cells, as these cells do not possess sufficient amounts of certain enzymes (e.g., superoxide dismutase, catalase, glutathione peroxidase) involved in detoxifying free radicals and protecting the cells from subsequent damage.
Indications
- For reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin hydrochloride dose of 300 mg/m^2 and would benefit from continued doxorubicin therapy. Also approved for the treatment of extravasation from intravenous anthracyclines.
- Save is indicated for the treatment of anthracycline extravasation.
- Dexrazoxane is indicated for reducing the incidence and severity of cardiomyopathy associated with the administration of doxorubicin in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/sq m of the body surface and who would benefit from continued therapy with doxorubicin.
- Accidental extravasation of chemotherapy containing anthracycline often causes mutilating complications as a result of extensive tissue necrosis. Treatment, therefore, consists of extensive surgical debridement.
- Reducing incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m2 and who will continue to receive doxorubicin.
FDA-approved indications:
- Reduction of incidence and severity of cardiac dysfunction associated with anthracycline use.
- Dexrazoxane can also be used to treat tissue damage caused by anthracyclines when they leak from the vein while being administered.
Non-FDA-approved indication:
- Although a study is still underway as of this writing, dexrazoxane may act as a beneficial neuroprotectant to treat neurodegeneration in patients with Parkinson’s disease.[rx]
Use in Cancer
Dexrazoxane hydrochloride is approved to treat severe side effects caused by certain types of chemotherapy. It is used to treat the following:
- Cardiac (heart) side effects caused by doxorubicin hydrochloride in women being treated for metastatic breast cancer. Dexrazoxane hydrochloride helps make the side effects happen less often and makes them less severe when they do occur. It is used only in women who have already received high doses of doxorubicin and continue to be treated with it. This use is approved for the Totect and Zinecard brands of dexrazoxane hydrochloride.
- Extravasation caused by intravenous anthracyclines. Extravasation occurs when injected drugs leak out of the vein, into the surrounding tissue. This can cause redness, pain, and swelling, and may damage the tissue. This use is approved for the Totect brand of dexrazoxane hydrochloride.
Contraindications
- decreased blood platelets
- low levels of white blood cells
- low levels of a type of white blood cell called neutrophils
- pregnancy
- a patient who is producing milk and breastfeeding
- chronic kidney disease stage 3B (moderate)
- chronic kidney disease stage 4 (severe)
- chronic kidney disease stage 5 (failure)
- kidney disease with likely reduction in kidney function
Dosage
Strengths: 250 mg; 500 mg
Cardiomyopathy Prophylaxis
The dosage ratio of dexrazoxane to doxorubicin is 10:1 (e.g. 500 mg/m2 dexrazoxane to 50 mg/m2 doxorubicin)
- Administer via IV infusion over 15 minutes.
- DO NOT administer via IV push.
- Administer doxorubicin within 30 minutes of completion of dexrazoxane infusion; do not administer doxorubicin before dexrazoxane.
- Do not use it with the initiation of doxorubicin therapy.
Extravasation
Recommended doses:
- Day one: 1000 mg/m2 IV over 1 to 2 hours
- Day two: 1000 mg/m2 IV over 1 to 2 hours
- Day three: 500 mg/m2 IV over 1 to 2 hours
Maximum doses:
- Day one: 2000 mg
- Day two: 2000 mg
- Day three: 1000 mg
- The product must be diluted with 50 mL of 0.167 M sodium lactate injection solution prior to administration.
- Initiate the first infusion as soon as possible and within the first 6 hours of extravasation.
- Start day 2 and 3 treatments at the same hour as the first day (give or take 3 hours).
- Remove cooling features such as ice packs (if used) at least 15 minutes before administration to allow sufficient blood flow to the extravasation area.
Side Effects
The Most Common
- pain or swelling in the place where the medication was injected
- nausea
- vomiting
- diarrhea
- constipation
- stomach pain
- loss of appetite
- dizziness
- headache
- excessive tiredness
- difficulty falling asleep or staying asleep
- depression
- swelling of the arms, hands, feet, ankles, or lower legs
- sore throat, fever, chills, cough, and other signs of infection
- unusual bruising or bleeding
- pale skin
- weakness
- shortness of breath
- rash
- itching
- hives
- difficulty breathing or swallowing
- swelling of the eyes, face, mouth, lips, tongue, or throat
- dizziness
- fainting
More common
- Blurred or double vision
- diarrhea
- difficulty having a bowel movement
- difficulty in swallowing
- difficulty in walking
- discouragement
- dizziness
- drooping eyelids
- fainting
- feeling sad or empty
- hair loss
- headache
- heartburn
- irritability
- jaw pain
- lack or loss of appetite
- lightheadedness
- loss of interest or pleasure
- muscle pain, spasms, cramps, or stiffness
- nausea
- numbness or tingling in the fingers and toes
- pain in the fingers and toes
- pain in the testicles
- pain or burning in the throat
- pain or redness at the site of injection
- pale skin at the site of injection
- rapid, shallow breathing
- stomach pain
- swelling or inflammation of the mouth
- thinning of the hair
- trouble concentrating
- trouble sleeping
- vomiting
- weight loss
Rare
- Bluish color
- changes in skin color
- chest pain or tightness
- chills
- cold hands and feet
- cough
- fever
- hoarseness
- lower back or side pain
- pain, redness, or swelling in the arm or leg
- painful or difficult urination
- pale skin
- sneezing
- sore throat
- swelling of the hands, ankles, feet, or lower legs
- tenderness
- trouble breathing
- unusual bleeding or bruising
- unusual tiredness or weakness
- Black, tarry stools
- chest discomfort
- fast, irregular, or pounding heartbeat
- pain at the injection site
- ulcers, sores, or white spots in the mouth
Drug Interactions
| DRUG | INTERACTION |
|---|---|
| Abacavir | Dexrazoxane may decrease the excretion rate of Abacavir which could result in a higher serum level. |
| Abatacept | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Abatacept. |
| Abciximab | The risk or severity of bleeding can be increased when Abciximab is combined with Dexrazoxane. |
| Aceclofenac | Aceclofenac may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Acemetacin | Acemetacin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Acenocoumarol | The risk or severity of bleeding can be increased when Acenocoumarol is combined with Dexrazoxane. |
| Acetaminophen | Acetaminophen may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Acetazolamide | Acetazolamide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. |
| Acetylsalicylic acid | The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Dexrazoxane. |
| Aclidinium | Dexrazoxane may decrease the excretion rate of Aclidinium which could result in a higher serum level. |
| Acrivastine | Dexrazoxane may decrease the excretion rate of Acrivastine which could result in a higher serum level. |
| Acyclovir | Acyclovir may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Dexrazoxane. |
| Adefovir dipivoxil | Adefovir dipivoxil may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Adenovirus | The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Dexrazoxane. |
| Albutrepenonacog | Dexrazoxane may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level. |
| Alclofenac | Alclofenac may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Aldesleukin | The risk or severity of adverse effects can be increased when Aldesleukin is combined with Dexrazoxane. |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Dexrazoxane. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dexrazoxane. |
| Allogeneic | The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Dexrazoxane. |
| Allopurinol | The risk or severity of adverse effects can be increased when Allopurinol is combined with Dexrazoxane. |
| Almasilate | Dexrazoxane may decrease the excretion rate of Almasilate which could result in a higher serum level. |
| Almotriptan | Dexrazoxane may decrease the excretion rate of Almotriptan which could result in a higher serum level. |
| Alogliptin | Dexrazoxane may decrease the excretion rate of Alogliptin which could result in a higher serum level. |
| Alprazolam | Dexrazoxane may decrease the excretion rate of Alprazolam which could result in a higher serum level. |
| Alteplase | The risk or severity of bleeding can be increased when Alteplase is combined with Dexrazoxane. |
| Altretamine | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Altretamine. |
| Amantadine | Dexrazoxane may decrease the excretion rate of Amantadine which could result in a higher serum level. |
| Amikacin | Dexrazoxane may decrease the excretion rate of Amikacin which could result in a higher serum level. |
| Amiloride | Amiloride may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. |
| Aminophenazone | Aminophenazone may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Amitriptyline | Amitriptyline may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Ammonium chloride | Dexrazoxane may decrease the excretion rate of Ammonium chloride which could result in a higher serum level. |
| Amoxicillin | Dexrazoxane may decrease the excretion rate of Amoxicillin which could result in a higher serum level. |
| Amphetamine | Amphetamine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Amphotericin B | Amphotericin B may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Ampicillin | Dexrazoxane may decrease the excretion rate of Ampicillin which could result in a higher serum level. |
| Amrinone | Dexrazoxane may decrease the excretion rate of Amrinone which could result in a higher serum level. |
| Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with Dexrazoxane. |
| Anagrelide | The risk or severity of bleeding can be increased when Anagrelide is combined with Dexrazoxane. |
| Anakinra | The risk or severity of adverse effects can be increased when Anakinra is combined with Dexrazoxane. |
| Ancestim | Dexrazoxane may decrease the excretion rate of Ancestim which could result in a higher serum level. |
| Ancrod | The risk or severity of bleeding can be increased when Ancrod is combined with Dexrazoxane. |
| Anifrolumab | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Anifrolumab. |
| Anistreplase | The risk or severity of bleeding can be increased when Anistreplase is combined with Dexrazoxane. |
| Anthrax immune | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Dexrazoxane. |
| Anthrax vaccine | The risk or severity of infection can be increased when Anthrax vaccine is combined with Dexrazoxane. |
| Antihemophilic | Dexrazoxane may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level. |
| antilymphocyte | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Antilymphocyte immunoglobulin (horse). |
| Antipyrine | Antipyrine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Antithrombin Alfa | The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Dexrazoxane. |
| Antithrombin III human | Dexrazoxane may decrease the excretion rate of Antithrombin III human which could result in a higher serum level. |
| Antithymocyte | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dexrazoxane. |
| Antrafenine | Antrafenine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Apalutamide | Dexrazoxane may decrease the excretion rate of Apalutamide which could result in a higher serum level. |
| Apixaban | The risk or severity of bleeding can be increased when Apixaban is combined with Dexrazoxane. |
| Apremilast | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Apremilast. |
| Ardeparin | The risk or severity of bleeding can be increased when Ardeparin is combined with Dexrazoxane. |
| Arformoterol | Dexrazoxane may decrease the excretion rate of Arformoterol which could result in a higher serum level. |
| Argatroban | The risk or severity of bleeding can be increased when Argatroban is combined with Dexrazoxane. |
| Arsenic trioxide | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Arsenic trioxide. |
| COVID-19 Vaccine | The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Dexrazoxane. |
| Atazanavir | Atazanavir may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Atomoxetine | Atomoxetine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Auranofin | Dexrazoxane may decrease the excretion rate of Auranofin which could result in a higher serum level. |
| Aurothioglucose | Dexrazoxane may decrease the excretion rate of Aurothioglucose which could result in a higher serum level. |
| Azacitidine | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Azacitidine. |
| Azathioprine | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Azathioprine. |
| Azelaic acid | Dexrazoxane may decrease the excretion rate of Azelaic acid which could result in a higher serum level. |
| Aztreonam | Aztreonam may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Bacillus antigen | The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Dexrazoxane. |
| Bacillus calmette | The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Dexrazoxane. |
| Bacillus antigen | The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Dexrazoxane. |
| Bacitracin | Bacitracin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Baclofen | Baclofen may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Balsalazide | Balsalazide may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Baricitinib | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Baricitinib. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Dexrazoxane. |
| BCG vaccine | The risk or severity of infection can be increased when BCG vaccine is combined with Dexrazoxane. |
| Beclomethasone | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Beclomethasone dipropionate. |
| Belatacept | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Belatacept. |
| Belimumab | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Belimumab. |
| Belinostat | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Belinostat. |
| Belumosudil | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Belumosudil. |
| Bemiparin | The risk or severity of bleeding can be increased when Bemiparin is combined with Dexrazoxane. |
| Bendamustine | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Bendamustine. |
| Bendroflumethiazide | Bendroflumethiazide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. |
| Benorilate | Benorilate may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Benoxaprofen | Benoxaprofen may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Benserazide | Dexrazoxane may decrease the excretion rate of Benserazide which could result in a higher serum level. |
| Benzatropine | Benzatropine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Benznidazole | Dexrazoxane may decrease the excretion rate of Benznidazole which could result in a higher serum level. |
| Benzthiazide | Benzthiazide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. |
| Benzydamine | Benzydamine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Bepotastine | Dexrazoxane may decrease the excretion rate of Bepotastine which could result in a higher serum level. |
| Betamethasone | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Betamethasone. |
| Betrixaban | The risk or severity of bleeding can be increased when Betrixaban is combined with Dexrazoxane. |
| Bexarotene | The risk or severity of adverse effects can be increased when Bexarotene is combined with Dexrazoxane. |
| Bicisate | Dexrazoxane may decrease the excretion rate of Bicisate which could result in a higher serum level. |
| Bimekizumab | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Bimekizumab. |
| Bismuth subgallate | Dexrazoxane may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level. |
| Bisoprolol | Dexrazoxane may decrease the excretion rate of Bisoprolol which could result in a higher serum level. |
| Bisoxatin | Dexrazoxane may decrease the excretion rate of Bisoxatin which could result in a higher serum level. |
| Bivalirudin | The risk or severity of bleeding can be increased when Bivalirudin is combined with Dexrazoxane. |
| Bleomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Dexrazoxane. |
| Blinatumomab | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Blinatumomab. |
| Bordetella | The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Dexrazoxane. |
| Bortezomib | The risk or severity of adverse effects can be increased when Bortezomib is combined with Dexrazoxane. |
| Bosutinib | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Bosutinib. |
| Brentuximab | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Brentuximab vedotin. |
| Brivaracetam | Dexrazoxane may decrease the excretion rate of Brivaracetam which could result in a higher serum level. |
| Brodalumab | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Brodalumab. |
| Bromazepam | Dexrazoxane may decrease the excretion rate of Bromazepam which could result in a higher serum level. |
| Bromotheophylline | Bromotheophylline may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. |
| Budesonide | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Budesonide. |
| Bumadizone | Bumadizone may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Bumetanide | Bumetanide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. |
| Bupropion | Dexrazoxane may decrease the excretion rate of Bupropion which could result in a higher serum level. |
| Buspirone | Dexrazoxane may decrease the excretion rate of Buspirone which could result in a higher serum level. |
| Busulfan | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Busulfan. |
| Butabarbital | Butabarbital may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Cabazitaxel | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Cabazitaxel. |
| Canagliflozin | Canagliflozin may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. |
| Canakinumab | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Canakinumab. |
| Cangrelor | The risk or severity of bleeding can be increased when Cangrelor is combined with Dexrazoxane. |
| Canrenoic acid | Canrenoic acid may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. |
| Capecitabine | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Capecitabine. |
| Caplacizumab | The risk or severity of bleeding can be increased when Caplacizumab is combined with Dexrazoxane. |
| Capreomycin | Dexrazoxane may decrease the excretion rate of Capreomycin which could result in a higher serum level. |
| Carbamazepine | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Carbamazepine. |
| Carbidopa | Carbidopa may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Carboplatin | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Carboplatin. |
| Carfilzomib | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Carfilzomib. |
| Carmustine | The risk or severity of adverse effects can be increased when Carmustine is combined with Dexrazoxane. |
| Carprofen | Carprofen may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Cefaclor | Cefaclor may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Cefadroxil | Cefadroxil may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Cefalotin | Cefalotin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Cefamandole | Cefamandole may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Cefapirin | Cefapirin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Cefazolin | Cefazolin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Cefdinir | Dexrazoxane may decrease the excretion rate of Cefdinir which could result in a higher serum level. |
| Cefditoren | Cefditoren may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Cefepime | Cefepime may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Cefmenoxime | Cefmenoxime may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Cefmetazole | Cefmetazole may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Cefonicid | Cefonicid may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Cefoperazone | Cefoperazone may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Ceforanide | Ceforanide may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Cefotaxime | Cefotaxime may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Cefotetan | Cefotetan may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Cefotiam | Cefotiam may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Cefoxitin | Cefoxitin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Cefpiramide | Cefpiramide may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Cefpirome | Cefpirome may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Cefpodoxime | Cefpodoxime may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Cefprozil | Cefprozil may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Cefradine | Cefradine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Ceftaroline fosamil | Ceftaroline fosamil may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Ceftazidime | Ceftazidime may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Ceftibuten | Ceftibuten may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Ceftizoxime | Ceftizoxime may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Ceftobiprole | Ceftobiprole may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Ceftolozane | Dexrazoxane may decrease the excretion rate of Ceftolozane which could result in a higher serum level. |
| Ceftriaxone | Ceftriaxone may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Cefuroxime | Cefuroxime may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Celecoxib | Celecoxib may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Cephalexin | Cephalexin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Cephaloglycin | Cephaloglycin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Certolizumab pegol | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Certolizumab pegol. |
| Cetirizine | Cetirizine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Cevimeline | Cevimeline may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Chloral hydrate | Dexrazoxane may decrease the excretion rate of Chloral hydrate which could result in a higher serum level. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Chlorambucil is combined with Dexrazoxane. |
| Chloramphenicol | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Chloramphenicol. |
| Chloroquine | Dexrazoxane may decrease the excretion rate of Chloroquine which could result in a higher serum level. |
| Chlorothiazide | Chlorothiazide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. |
| Chloroxylenol | Dexrazoxane may decrease the excretion rate of Chloroxylenol which could result in a higher serum level. |
| Chlorpromazine | Dexrazoxane may decrease the excretion rate of Chlorpromazine which could result in a higher serum level. |
| Chlorpropamide | Dexrazoxane may decrease the excretion rate of Chlorpropamide which could result in a higher serum level. |
| Chlorthalidone | Chlorthalidone may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. |
| Chlorzoxazone | Chlorzoxazone may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Choline C 11 | Dexrazoxane may decrease the excretion rate of Choline C 11 which could result in a higher serum level. |
| Choline magnesium | Choline magnesium trisalicylate may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Choline salicylate | Dexrazoxane may decrease the excretion rate of Choline salicylate which could result in a higher serum level. |
| Chondroitin sulfate | Dexrazoxane may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level. |
| Chromic chloride | Dexrazoxane may decrease the excretion rate of Chromic chloride which could result in a higher serum level. |
| Chromic nitrate | Dexrazoxane may decrease the excretion rate of Chromic nitrate which could result in a higher serum level. |
| Chromium | Dexrazoxane may decrease the excretion rate of Chromium which could result in a higher serum level. |
| Chromium gluconate | Dexrazoxane may decrease the excretion rate of Chromium gluconate which could result in a higher serum level. |
| Chromium nicotinate | Dexrazoxane may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level. |
| Chromous sulfate | Dexrazoxane may decrease the excretion rate of Chromous sulfate which could result in a higher serum level. |
| Ciclesonide | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Ciclesonide. |
| Cidofovir | Cidofovir may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Cilostazol | The risk or severity of bleeding can be increased when Cilostazol is combined with Dexrazoxane. |
| Cimetidine | Dexrazoxane may decrease the excretion rate of Cimetidine which could result in a higher serum level. |
| Ciprofloxacin | Dexrazoxane may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level. |
| Cisplatin | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Cisplatin. |
| Cladribine | The risk or severity of adverse effects can be increased when Cladribine is combined with Dexrazoxane. |
| Clevidipine | Dexrazoxane may decrease the excretion rate of Clevidipine which could result in a higher serum level. |
| Clobazam | Clobazam may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Clobetasol propionate | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Clobetasol propionate. |
| Clofarabine | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Clofarabine. |
| Clomipramine | Dexrazoxane may decrease the excretion rate of Clomipramine which could result in a higher serum level. |
| Clonazepam | Dexrazoxane may decrease the excretion rate of Clonazepam which could result in a higher serum level. |
| Clopidogrel | The risk or severity of bleeding can be increased when Clopidogrel is combined with Dexrazoxane. |
| Clorazepic acid | Dexrazoxane may decrease the excretion rate of Clorazepic acid which could result in a higher serum level. |
| Clostridium | The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Dexrazoxane. |
| Clove oil | Dexrazoxane may decrease the excretion rate of Clove oil which could result in a higher serum level. |
| Clozapine | The risk or severity of neutropenia can be increased when Dexrazoxane is combined with Clozapine. |
| Colchicine | Dexrazoxane may decrease the excretion rate of Colchicine which could result in a higher serum level. |
| Colistimethate | Colistimethate may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Colistin | Dexrazoxane may decrease the excretion rate of Colistin which could result in a higher serum level. |
| Conivaptan | Conivaptan may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. |
| Conjugated estrogens | Conjugated estrogens may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Corifollitropin alfa | Dexrazoxane may decrease the excretion rate of Corifollitropin alfa which could result in a higher serum level. |
| Corticotropin | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Corticotropin. |
| Cortisone acetate | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Cortisone acetate. |
| Corynebacterium | The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Dexrazoxane. |
| Cyanocobalamin | The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Dexrazoxane. |
| Cyclopenthiazide | Cyclopenthiazide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. |
| Cyclophosphamide | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Cyclophosphamide. |
| Cyclosporine | Dexrazoxane may increase the immunosuppressive activities of Cyclosporine. |
| Cyclothiazide | Cyclothiazide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. |
| Cytarabine | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Cytarabine. |
| Dabigatran | The risk or severity of bleeding can be increased when Dabigatran is combined with Dexrazoxane. |
| Dabigatran etexilate | Dexrazoxane may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Dacarbazine. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Dactinomycin. |
| Dalfampridine | Dexrazoxane may decrease the excretion rate of Dalfampridine which could result in a higher serum level. |
| Dalteparin | The risk or severity of bleeding can be increased when Dalteparin is combined with Dexrazoxane. |
| Danaparoid | The risk or severity of bleeding can be increased when Danaparoid is combined with Dexrazoxane. |
| Dapagliflozin | Dapagliflozin may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. |
| Daptomycin | Daptomycin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Dasatinib | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Dasatinib. |
| Daunorubicin | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Daunorubicin. |
| Decitabine | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Decitabine. |
| Deferiprone | Dexrazoxane may decrease the excretion rate of Deferiprone which could result in a higher serum level. |
| Defibrotide | The risk or severity of bleeding can be increased when Defibrotide is combined with Dexrazoxane. |
| Deflazacort | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Deflazacort. |
| Delafloxacin | Dexrazoxane may decrease the excretion rate of Delafloxacin which could result in a higher serum level. |
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Dexrazoxane. |
| Desipramine | Dexrazoxane may decrease the excretion rate of Desipramine which could result in a higher serum level. |
| Desirudin | The risk or severity of bleeding can be increased when Desirudin is combined with Dexrazoxane. |
| Desmopressin | Desmopressin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Desoximetasone | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Desoximetasone. |
| Desvenlafaxine | Dexrazoxane may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level. |
| Deucravacitinib | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Deucravacitinib. |
| Deutetrabenazine | Dexrazoxane may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level. |
| Dexamethasone | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Dexamethasone. |
| Dexibuprofen | Dexibuprofen may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Dexketoprofen | Dexketoprofen may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Dexmedetomidine | Dexrazoxane may decrease the excretion rate of Dexmedetomidine which could result in a higher serum level. |
| Dexpanthenol | Dexrazoxane may decrease the excretion rate of Dexpanthenol which could result in a higher serum level. |
| Dextran | Dexrazoxane may decrease the excretion rate of Dextran which could result in a higher serum level. |
| Diatrizoate | Diatrizoate may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Diazepam | Dexrazoxane may decrease the excretion rate of Diazepam which could result in a higher serum level. |
| Dichlorobenzyl | Dexrazoxane may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level. |
| Diclofenac | Diclofenac may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Diclofenamide | Diclofenamide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. |
| Dicoumarol | The risk or severity of bleeding can be increased when Dicoumarol is combined with Dexrazoxane. |
| Dicyclomine | Dexrazoxane may decrease the excretion rate of Dicyclomine which could result in a higher serum level. |
| Didanosine | Dexrazoxane may decrease the excretion rate of Didanosine which could result in a higher serum level. |
| Dienogest | Dexrazoxane may decrease the excretion rate of Dienogest which could result in a higher serum level. |
| Diflunisal | Diflunisal may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Difluocortolone | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Difluocortolone. |
| Digoxin | Dexrazoxane may decrease the excretion rate of Digoxin which could result in a higher serum level. |
| Dihydrostreptomycin | Dihydrostreptomycin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Dimercaprol | Dexrazoxane may decrease the excretion rate of Dimercaprol which could result in a higher serum level. |
| Dimethyl fumarate | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Dimethyl fumarate. |
| Dimethyl sulfoxide | The therapeutic efficacy of Dexrazoxane can be decreased when used in combination with Dimethyl sulfoxide. |
| Dinutuximab | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Dinutuximab. |
| Dipyridamole | The risk or severity of bleeding can be increased when Dipyridamole is combined with Dexrazoxane. |
| Diroximel fumarate | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Diroximel fumarate. |
| Disopyramide | Disopyramide may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| DMethylephedrine | Dexrazoxane may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level. |
| Dobutamine | Dexrazoxane may decrease the excretion rate of Dobutamine which could result in a higher serum level. |
| Docetaxel | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Docetaxel. |
| Dopamine | Dexrazoxane may decrease the excretion rate of Dopamine which could result in a higher serum level. |
| Doripenem | Dexrazoxane may decrease the excretion rate of Doripenem which could result in a higher serum level. |
| Doxacurium | Dexrazoxane may decrease the excretion rate of Doxacurium which could result in a higher serum level. |
| Doxepin | Dexrazoxane may decrease the excretion rate of Doxepin which could result in a higher serum level. |
| Doxorubicin | The therapeutic efficacy of Doxorubicin can be decreased when used in combination with Dexrazoxane. |
| Doxycycline | Doxycycline may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Drospirenone | Drospirenone may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. |
| Drotrecogin alfa | The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Dexrazoxane. |
| Droxidopa | Dexrazoxane may decrease the excretion rate of Droxidopa which could result in a higher serum level. |
| Duloxetine | Dexrazoxane may decrease the excretion rate of Duloxetine which could result in a higher serum level. |
| Dyphylline | Dexrazoxane may decrease the excretion rate of Dyphylline which could result in a higher serum level. |
| Ebola Zaire] | The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Dexrazoxane. |
| Eculizumab | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Eculizumab. |
| Edetic acid | The risk or severity of bleeding can be increased when Edetic acid is combined with Dexrazoxane. |
| Edoxaban | Dexrazoxane may decrease the excretion rate of Edoxaban which could result in a higher serum level. |
| Edrophonium | Dexrazoxane may decrease the excretion rate of Edrophonium which could result in a higher serum level. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Dexrazoxane. |
| Emapalumab | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Emapalumab. |
| Enalaprilat | Dexrazoxane may decrease the excretion rate of Enalaprilat which could result in a higher serum level. |
| Enoxaparin | The risk or severity of bleeding can be increased when Enoxaparin is combined with Dexrazoxane. |
| Enzalutamide | Dexrazoxane may decrease the excretion rate of Enzalutamide which could result in a higher serum level. |
| Epirubicin | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Epirubicin. |
| Eplerenone | Eplerenone may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. |
| Epoprostenol | The risk or severity of bleeding can be increased when Epoprostenol is combined with Dexrazoxane. |
| Eptifibatide | The risk or severity of bleeding can be increased when Eptifibatide is combined with Dexrazoxane. |
| Eribulin | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Eribulin. |
| Ertapenem | Ertapenem may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Ertugliflozin | Ertugliflozin may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. |
| Estazolam | Dexrazoxane may decrease the excretion rate of Estazolam which could result in a higher serum level. |
| Estradiol | Dexrazoxane may decrease the excretion rate of Estradiol which could result in a higher serum level. |
| Estradiol acetate | Dexrazoxane may decrease the excretion rate of Estradiol acetate which could result in a higher serum level. |
| Estradiol cypionate | Dexrazoxane may decrease the excretion rate of Estradiol cypionate which could result in a higher serum level. |
| Estradiol dienanthate | Dexrazoxane may decrease the excretion rate of Estradiol dienanthate which could result in a higher serum level. |
| Estradiol valerate | Dexrazoxane may decrease the excretion rate of Estradiol valerate which could result in a higher serum level. |
| Estramustine | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Estramustine. |
| Estrone sulfate | Dexrazoxane may decrease the excretion rate of Estrone sulfate which could result in a higher serum level. |
| Eszopiclone | Dexrazoxane may decrease the excretion rate of Eszopiclone which could result in a higher serum level. |
| Etacrynic acid | Etacrynic acid may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. |
| Etafedrine | Dexrazoxane may decrease the excretion rate of Etafedrine which could result in a higher serum level. |
| Etanercept | The risk or severity of adverse effects can be increased when Etanercept is combined with Dexrazoxane. |
| Ethambutol | Ethambutol may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Etodolac | Etodolac may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Etomidate | Etomidate may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Etonogestrel | Etonogestrel may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Etoposide | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Etoposide. |
| Etoricoxib | Etoricoxib may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Eucalyptus oil | Dexrazoxane may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level. |
| Everolimus | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Everolimus. |
| Ezogabine | Dexrazoxane may decrease the excretion rate of Ezogabine which could result in a higher serum level. |
| Famtozinameran | The therapeutic efficacy of Famtozinameran can be decreased when used in combination with Dexrazoxane. |
| Fenbufen | Fenbufen may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Fenofibrate | Dexrazoxane may decrease the excretion rate of Fenofibrate which could result in a higher serum level. |
| Fenofibric acid | Dexrazoxane may decrease the excretion rate of Fenofibric acid which could result in a higher serum level. |
| Fenoldopam | Dexrazoxane may decrease the excretion rate of Fenoldopam which could result in a higher serum level. |
| Fenoprofen | Fenoprofen may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Fentanyl | Dexrazoxane may decrease the excretion rate of Fentanyl which could result in a higher serum level. |
| Fesoterodine | Dexrazoxane may decrease the excretion rate of Fesoterodine which could result in a higher serum level. |
| Filgotinib | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Filgotinib. |
| Finerenone | Finerenone may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. |
| Fingolimod | Dexrazoxane may increase the immunosuppressive activities of Fingolimod. |
| Flavoxate | Dexrazoxane may decrease the excretion rate of Flavoxate which could result in a higher serum level. |
| Floctafenine | Floctafenine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Florbetaben (18F) | Dexrazoxane may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level. |
| Florbetapir (18F) | Dexrazoxane may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level. |
| Floxuridine | The risk or severity of adverse effects can be increased when Floxuridine is combined with Dexrazoxane. |
| Fluconazole | Fluconazole may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Flucytosine | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Flucytosine. |
| Fludarabine | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Fludarabine. |
| Fludeoxyglucose | Dexrazoxane may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level. |
| Fludrocortisone | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Fludrocortisone. |
| Fluindione | The risk or severity of bleeding can be increased when Fluindione is combined with Dexrazoxane. |
| Flumazenil | Dexrazoxane may decrease the excretion rate of Flumazenil which could result in a higher serum level. |
| Flunisolide | The risk or severity of adverse effects can be increased when Flunisolide is combined with Dexrazoxane. |
| Fluocinolone | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Fluocinolone acetonide. |
| Fluocinonide | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Fluocinonide. |
| Fluocortolone | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Fluocortolone. |
| Fluorometholone | The risk or severity of adverse effects can be increased when Fluorometholone is combined with Dexrazoxane. |
| Fluorouracil | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Fluorouracil. |
| Flupentixol | The risk or severity of myelosuppression can be increased when Flupentixol is combined with Dexrazoxane. |
| Fluprednisolone | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Fluprednisolone. |
| Flurazepam | Dexrazoxane may decrease the excretion rate of Flurazepam which could result in a higher serum level. |
| Flurbiprofen | Flurbiprofen may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Flutamide | Dexrazoxane may decrease the excretion rate of Flutamide which could result in a higher serum level. |
| Fluticasone | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Fluticasone. |
| Fluticasone furoate | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Fluticasone furoate. |
| Fluticasone | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Fluticasone propionate. |
| Fluvoxamine | Fluvoxamine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Folic acid | Folic acid may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Fomepizole | Dexrazoxane may decrease the excretion rate of Fomepizole which could result in a higher serum level. |
| Fondaparinux | Dexrazoxane may decrease the excretion rate of Fondaparinux which could result in a higher serum level. |
| Formestane | Dexrazoxane may decrease the excretion rate of Formestane which could result in a higher serum level. |
| Foscarnet | Foscarnet may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Fosfomycin | Dexrazoxane may decrease the excretion rate of Fosfomycin which could result in a higher serum level. |
| Fosinopril | Dexrazoxane may decrease the excretion rate of Fosinopril which could result in a higher serum level. |
| Framycetin | Framycetin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Furosemide | Furosemide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. |
| Gabapentin enacarbil | Dexrazoxane may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level. |
| Gadobenic acid | Dexrazoxane may decrease the excretion rate of Gadobenic acid which could result in a higher serum level. |
| Gadodiamide | Gadodiamide may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Gadofosveset | Dexrazoxane may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level. |
| Gadopentetic acid | Dexrazoxane may decrease the excretion rate of Gadopentetic acid which could result in a higher serum level. |
| Gadoteric acid | Dexrazoxane may decrease the excretion rate of Gadoteric acid which could result in a higher serum level. |
| Gadoteridol | Dexrazoxane may decrease the excretion rate of Gadoteridol which could result in a higher serum level. |
| Gallium nitrate | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Gallium nitrate. |
| Ganciclovir | Dexrazoxane may decrease the excretion rate of Ganciclovir which could result in a higher serum level. |
| Gemcitabine | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Gemcitabine. |
| Gemfibrozil | Dexrazoxane may decrease the excretion rate of Gemfibrozil which could result in a higher serum level. |
| Gemtuzumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dexrazoxane. |
| Gentamicin | Dexrazoxane may decrease the excretion rate of Gentamicin which could result in a higher serum level. |
| Gimeracil | Dexrazoxane may decrease the excretion rate of Gimeracil which could result in a higher serum level. |
| Givosiran | Givosiran may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Glatiramer | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Glatiramer. |
| Glipizide | Dexrazoxane may decrease the excretion rate of Glipizide which could result in a higher serum level. |
| Glycerol | Dexrazoxane may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level. |
| Golimumab | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Golimumab. |
| Golodirsen | Dexrazoxane may decrease the excretion rate of Golodirsen which could result in a higher serum level. |
| Goserelin | Goserelin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Guanethidine | Dexrazoxane may decrease the excretion rate of Guanethidine which could result in a higher serum level. |
| Guanfacine | Dexrazoxane may decrease the excretion rate of Guanfacine which could result in a higher serum level. |
| Guselkumab | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Guselkumab. |
| Hydralazine | Dexrazoxane may decrease the excretion rate of Hydralazine which could result in a higher serum level. |
| Hydrochlorothiazide | Hydrochlorothiazide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. |
| Hydrocortisone | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Hydrocortisone acetate. |
| Hydrocortisone | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Hydrocortisone butyrate. |
| Hydrocortisone | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Hydrocortisone succinate. |
| Hydroflumethiazide | Hydroflumethiazide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. |
| Hydromorphone | Hydromorphone may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Hydroxocobalamin | Hydroxocobalamin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Hydroxychloroquine | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Hydroxychloroquine. |
| Hydroxyethyl Starch | Dexrazoxane may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Hydroxyurea. |
| Ibritumomab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dexrazoxane. |
| Ibrutinib | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Ibrutinib. |
| Ibuprofen | Ibuprofen may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Ibutilide | Ibutilide may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Icatibant | Dexrazoxane may decrease the excretion rate of Icatibant which could result in a higher serum level. |
| Icosapent | Icosapent may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Icosapent ethyl | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Dexrazoxane. |
| Idarubicin | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Idarubicin. |
| Idarucizumab | Dexrazoxane may decrease the excretion rate of Idarucizumab which could result in a higher serum level. |
| Idebenone | Dexrazoxane may decrease the excretion rate of Idebenone which could result in a higher serum level. |
| Idelalisib | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Idelalisib. |
| Ifosfamide | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Ifosfamide. |
| Iloprost | The risk or severity of bleeding can be increased when Iloprost is combined with Dexrazoxane. |
| Imatinib | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Imatinib. |
| Imipramine | Dexrazoxane may decrease the excretion rate of Imipramine which could result in a higher serum level. |
| Indapamide | Indapamide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. |
| Indigotindisulf | Dexrazoxane may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level. |
| Indomethacin | The risk or severity of adverse effects can be increased when Indomethacin is combined with Dexrazoxane. |
| Inebilizumab | The risk or severity of infection can be increased when Dexrazoxane is combined with Inebilizumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Dexrazoxane. |
| othalamic acid | Dexrazoxane may decrease the excretion rate of Iothalamic acid which could result in a higher serum level. |
| Ioversol | Dexrazoxane may decrease the excretion rate of Ioversol which could result in a higher serum level. |
| Ioxilan | Dexrazoxane may decrease the excretion rate of Ioxilan which could result in a higher serum level. |
| Ipecac | Dexrazoxane may decrease the excretion rate of Ipecac which could result in a higher serum level. |
| Ipilimumab | Dexrazoxane may decrease the excretion rate of Ipilimumab which could result in a higher serum level. |
| Irinotecan | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Irinotecan. |
| Isoniazid | Dexrazoxane may decrease the excretion rate of Isoniazid which could result in a higher serum level. |
| Isosorbide | Isosorbide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. |
| Isosorbide | Dexrazoxane may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level. |
| Isosulfan blue | Dexrazoxane may decrease the excretion rate of Isosulfan blue which could result in a higher serum level. |
| Isotretinoin | Dexrazoxane may decrease the excretion rate of Isotretinoin which could result in a higher serum level. |
| Isoxicam | Isoxicam may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Isradipine | Isradipine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Ixabepilone | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Ixabepilone. |
| Ixazomib | Dexrazoxane may decrease the excretion rate of Ixazomib which could result in a higher serum level. |
| Ixekizumab | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Ixekizumab. |
| COVID Vaccine | The therapeutic efficacy of Janssen COVID-19 Vaccine can be decreased when used in combination with Dexrazoxane. |
| Japanese encephalitis | The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Dexrazoxane. |
| Kanamycin | Dexrazoxane may decrease the excretion rate of Kanamycin which could result in a higher serum level. |
| Ketamine | Dexrazoxane may decrease the excretion rate of Ketamine which could result in a higher serum level. |
| Ketazolam | Dexrazoxane may decrease the excretion rate of Ketazolam which could result in a higher serum level. |
| Ketoprofen | Ketoprofen may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Ketorolac | Ketorolac may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Labetalol | Dexrazoxane may decrease the excretion rate of Labetalol which could result in a higher serum level. |
| Lamivudine | Dexrazoxane may decrease the excretion rate of Lamivudine which could result in a higher serum level. |
| Lamotrigine | Dexrazoxane may decrease the excretion rate of Lamotrigine which could result in a higher serum level. |
| Latamoxef | Latamoxef may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Ledipasvir | Dexrazoxane may decrease the excretion rate of Ledipasvir which could result in a higher serum level. |
| Leflunomide | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Leflunomide. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Lenalidomide. |
| Lepirudin | The risk or severity of bleeding can be increased when Lepirudin is combined with Dexrazoxane. |
| Lesinurad | Dexrazoxane may decrease the excretion rate of Lesinurad which could result in a higher serum level. |
| Leuprolide | Leuprolide may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Levobupivacaine | Dexrazoxane may decrease the excretion rate of Levobupivacaine which could result in a higher serum level. |
| Levocarnitine | Dexrazoxane may decrease the excretion rate of Levocarnitine which could result in a higher serum level. |
| Levocetirizine | Dexrazoxane may decrease the excretion rate of Levocetirizine which could result in a higher serum level. |
| Levofloxacin | Dexrazoxane may decrease the excretion rate of Levofloxacin which could result in a higher serum level. |
| Levosalbutamol | Dexrazoxane may decrease the excretion rate of Levosalbutamol which could result in a higher serum level. |
| Linezolid | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Linezolid. |
| Liothyronine | Liothyronine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Lipegfilgrastim | Dexrazoxane may increase the myelosuppressive activities of Lipegfilgrastim. |
| Lisinopril | Dexrazoxane may decrease the excretion rate of Lisinopril which could result in a higher serum level. |
| Lithium carbonate | Dexrazoxane may decrease the excretion rate of Lithium carbonate which could result in a higher serum level. |
| Lithium citrate | Lithium citrate may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Lixisenatide | Dexrazoxane may decrease the excretion rate of Lixisenatide which could result in a higher serum level. |
| Lofexidine | Dexrazoxane may decrease the excretion rate of Lofexidine which could result in a higher serum level. |
| Lomustine | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Lomustine. |
| Lopinavir | The serum concentration of Dexrazoxane can be increased when it is combined with Lopinavir. |
| Loracarbef | Loracarbef may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Lorazepam | Lorazepam may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Lorcaserin | Dexrazoxane may decrease the excretion rate of Lorcaserin which could result in a higher serum level. |
| Lornoxicam | Lornoxicam may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Lorpiprazole | Dexrazoxane may decrease the excretion rate of Lorpiprazole which could result in a higher serum level. |
| Loxoprofen | Loxoprofen may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Lubiprostone | Dexrazoxane may decrease the excretion rate of Lubiprostone which could result in a higher serum level. |
| Lumiracoxib | Lumiracoxib may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Macitentan | Dexrazoxane may decrease the excretion rate of Macitentan which could result in a higher serum level. |
| Magnesium | The serum concentration of Magnesium can be decreased when it is combined with Dexrazoxane. |
| Magnesium carbonate | Dexrazoxane may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level. |
| Magnesium chloride | Dexrazoxane may decrease the excretion rate of Magnesium chloride which could result in a higher serum level. |
| Magnesium | Dexrazoxane may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level. |
| Magnesium | Dexrazoxane may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level. |
| Mangafodipir | Dexrazoxane may decrease the excretion rate of Mangafodipir which could result in a higher serum level. |
| Mannitol | Mannitol may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. |
| Maprotiline | Dexrazoxane may decrease the excretion rate of Maprotiline which could result in a higher serum level. |
| Measles virus | The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Dexrazoxane. |
| Mecamylamine | Dexrazoxane may decrease the excretion rate of Mecamylamine which could result in a higher serum level. |
| Mechlorethamine | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Mechlorethamine. |
| Meclofenamic acid | Meclofenamic acid may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Medroxyprogesterone | Dexrazoxane may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level. |
| Mefenamic acid | Mefenamic acid may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Megestrol acetate | Megestrol acetate may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Meloxicam | Meloxicam may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Melphalan | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Melphalan. |
| Memantine | Dexrazoxane may decrease the excretion rate of Memantine which could result in a higher serum level. |
| Meningococcal | The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Dexrazoxane. |
| Meperidine | Dexrazoxane may decrease the excretion rate of Meperidine which could result in a higher serum level. |
| Mepivacaine | Dexrazoxane may decrease the excretion rate of Mepivacaine which could result in a higher serum level. |
| Mepolizumab | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Mepolizumab. |
| Meprednisone | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Meprednisone. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Mercaptopurine. |
| Meropenem | Dexrazoxane may decrease the excretion rate of Meropenem which could result in a higher serum level. |
| Mesalazine | Mesalazine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Metamfetamine | Dexrazoxane may decrease the excretion rate of Metamfetamine which could result in a higher serum level. |
| Metamizole | Metamizole may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Metaxalone | Dexrazoxane may decrease the excretion rate of Metaxalone which could result in a higher serum level. |
| Metformin | Metformin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Methadone | Methadone may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Methazolamide | Methazolamide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. |
| Methimazole | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Methimazole. |
| Methotrexate | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Methotrexate. |
| Methoxsalen | Dexrazoxane may decrease the excretion rate of Methoxsalen which could result in a higher serum level. |
| Methyldopa | Dexrazoxane may decrease the excretion rate of Methyldopa which could result in a higher serum level. |
| Methylene blue | Dexrazoxane may decrease the excretion rate of Methylene blue which could result in a higher serum level. |
| Methylnaltrexone | Dexrazoxane may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level. |
| Methylprednisolone | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Methylprednisolone. |
| Methyltestosterone | Dexrazoxane may decrease the excretion rate of Methyltestosterone which could result in a higher serum level. |
| Meticrane | Meticrane may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. |
| Metoclopramide | Dexrazoxane may decrease the excretion rate of Metoclopramide which could result in a higher serum level. |
| Metolazone | Metolazone may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. |
| Metoprolol | Metoprolol may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Metyrapone | Dexrazoxane may decrease the excretion rate of Metyrapone which could result in a higher serum level. |
| Midazolam | Dexrazoxane may decrease the excretion rate of Midazolam which could result in a higher serum level. |
| Migalastat | Dexrazoxane may decrease the excretion rate of Migalastat which could result in a higher serum level. |
| Milnacipran | Dexrazoxane may decrease the excretion rate of Milnacipran which could result in a higher serum level. |
| Milrinone | Milrinone may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Mirabegron | Dexrazoxane may decrease the excretion rate of Mirabegron which could result in a higher serum level. |
| Mitomycin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Dexrazoxane. |
| Mitoxantrone | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Mitoxantrone. |
| COVID-19 Vaccine | The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Dexrazoxane. |
| Modified vaccinia | The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Dexrazoxane. |
| Mometasone furoate | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Mometasone furoate. |
| Monomethyl fumarate | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Monomethyl fumarate. |
| Mosunetuzumab | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Mosunetuzumab. |
| Moxisylyte | Dexrazoxane may decrease the excretion rate of Moxisylyte which could result in a higher serum level. |
| Mumps virus | The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Dexrazoxane. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Dexrazoxane. |
| Muzolimine | Muzolimine may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. |
| Mycophenolate | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Mycophenolate mofetil. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Mycophenolic acid. |
| N-acetyltyrosine | Dexrazoxane may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level. |
| Nabumetone | Nabumetone may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Nadolol | Dexrazoxane may decrease the excretion rate of Nadolol which could result in a higher serum level. |
| Nadroparin | The risk or severity of bleeding can be increased when Nadroparin is combined with Dexrazoxane. |
| Naldemedine | Dexrazoxane may decrease the excretion rate of Naldemedine which could result in a higher serum level. |
| Nalmefene | Dexrazoxane may decrease the excretion rate of Nalmefene which could result in a higher serum level. |
| Naloxone | Dexrazoxane may decrease the excretion rate of Naloxone which could result in a higher serum level. |
| Naproxen | Naproxen may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Natalizumab | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Natalizumab. |
| Nateglinide | Dexrazoxane may decrease the excretion rate of Nateglinide which could result in a higher serum level. |
| Nedaplatin | Dexrazoxane may decrease the excretion rate of Nedaplatin which could result in a higher serum level. |
| Nedocromil | Dexrazoxane may decrease the excretion rate of Nedocromil which could result in a higher serum level. |
| Nefazodone | Dexrazoxane may decrease the excretion rate of Nefazodone which could result in a higher serum level. |
| Nelarabine | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Nelarabine. |
| Neomycin | Dexrazoxane may decrease the excretion rate of Neomycin which could result in a higher serum level. |
| Netilmicin | Dexrazoxane may decrease the excretion rate of Netilmicin which could result in a higher serum level. |
| Nicorandil | Dexrazoxane may decrease the excretion rate of Nicorandil which could result in a higher serum level. |
| Nifedipine | Dexrazoxane may decrease the excretion rate of Nifedipine which could result in a higher serum level. |
| Nilotinib | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Nilotinib. |
| Nilutamide | Dexrazoxane may decrease the excretion rate of Nilutamide which could result in a higher serum level. |
| Nimesulide | The risk or severity of bleeding can be increased when Nimesulide is combined with Dexrazoxane. |
| Nisoldipine | Dexrazoxane may decrease the excretion rate of Nisoldipine which could result in a higher serum level. |
| Nitric Oxide | Dexrazoxane may decrease the excretion rate of Nitric Oxide which could result in a higher serum level. |
| Nitrofurantoin | Dexrazoxane may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level. |
| Nitroprusside | Nitroprusside may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Nuvaxovid | The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Dexrazoxane. |
| Obinutuzumab | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Obinutuzumab. |
| Ocrelizumab | Ocrelizumab may increase the immunosuppressive activities of Dexrazoxane. |
| Octinoxate | Dexrazoxane may decrease the excretion rate of Octinoxate which could result in a higher serum level. |
| Ofatumumab | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Ofatumumab. |
| Olaparib | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Olaparib. |
| Olsalazine | Olsalazine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Opium | Dexrazoxane may decrease the excretion rate of Opium which could result in a higher serum level. |
| Oseltamivir | Oseltamivir may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Oxacillin | Dexrazoxane may decrease the excretion rate of Oxacillin which could result in a higher serum level. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Oxaliplatin. |
| Oxaprozin | Oxaprozin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Oxazepam | Dexrazoxane may decrease the excretion rate of Oxazepam which could result in a higher serum level. |
| Oxybenzone | Dexrazoxane may decrease the excretion rate of Oxybenzone which could result in a higher serum level. |
| Oxyphenbutazone | Oxyphenbutazone may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Oxyquinoline | Dexrazoxane may decrease the excretion rate of Oxyquinoline which could result in a higher serum level. |
| Ozanimod | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Ozanimod. |
| Paclitaxel | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Paclitaxel. |
| Palbociclib | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Palbociclib. |
| Palifermin | The therapeutic efficacy of Palifermin can be decreased when used in combination with Dexrazoxane. |
| Paliperidone | Dexrazoxane may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
| Palonosetron | Palonosetron may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Pamidronic acid | Pamidronic acid may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Panobinostat | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Panobinostat. |
| Pantoprazole | Pantoprazole may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Parecoxib | Parecoxib may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Parnaparin | The risk or severity of bleeding can be increased when Parnaparin is combined with Dexrazoxane. |
| Paromomycin | Paromomycin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Patent Blue | Dexrazoxane may decrease the excretion rate of Patent Blue which could result in a higher serum level. |
| Pazopanib | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Pazopanib. |
| Pegaptanib | Dexrazoxane may decrease the excretion rate of Pegaptanib which could result in a higher serum level. |
| Pegaspargase | The risk or severity of adverse effects can be increased when Pegaspargase is combined with Dexrazoxane. |
| Pegcetacoplan | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Pegcetacoplan. |
| Peginesatide | Dexrazoxane may decrease the excretion rate of Peginesatide which could result in a higher serum level. |
| Peginterferon alfa-2a | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Dexrazoxane. |
| Peginterferon alfa-2b | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Dexrazoxane. |
| Peginterferon beta-1a | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Peginterferon beta-1a. |
| Pemetrexed | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Pemetrexed. |
| Penbutolol | Dexrazoxane may decrease the excretion rate of Penbutolol which could result in a higher serum level. |
| Penicillamine | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Penicillamine. |
| Pentaerythritol | Dexrazoxane may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level. |
| Pentamidine | Pentamidine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Pentastarch | Dexrazoxane may decrease the excretion rate of Pentastarch which could result in a higher serum level. |
| Pentetic acid | Dexrazoxane may decrease the excretion rate of Pentetic acid which could result in a higher serum level. |
| Pentobarbital | Pentobarbital may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Pentosan polysulfate | The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Dexrazoxane. |
| Pentostatin | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Pentostatin. |
| Pentoxifylline | The risk or severity of bleeding can be increased when Pentoxifylline is combined with Dexrazoxane. |
| Perindopril | Dexrazoxane may decrease the excretion rate of Perindopril which could result in a higher serum level. |
| Permethrin | Dexrazoxane may decrease the excretion rate of Permethrin which could result in a higher serum level. |
| Pertussis vaccine | The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Dexrazoxane. |
| Phenazopyridine | Phenazopyridine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Phenelzine | Dexrazoxane may decrease the excretion rate of Phenelzine which could result in a higher serum level. |
| Phenindione | The risk or severity of bleeding can be increased when Phenindione is combined with Dexrazoxane. |
| Phenprocoumon | The risk or severity of bleeding can be increased when Phenprocoumon is combined with Dexrazoxane. |
| Phentolamine | Dexrazoxane may decrease the excretion rate of Phentolamine which could result in a higher serum level. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Phenylalanine is combined with Dexrazoxane. |
| Phenylbutazone | Phenylbutazone may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Pholcodine | Dexrazoxane may decrease the excretion rate of Pholcodine which could result in a higher serum level. |
| Phosphoric acid | Dexrazoxane may decrease the excretion rate of Phosphoric acid which could result in a higher serum level. |
| Phylloquinone | Dexrazoxane may decrease the excretion rate of Phylloquinone which could result in a higher serum level. |
| Picosulfuric acid | Dexrazoxane may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level. |
| Pimecrolimus | The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Dexrazoxane. |
| Pindolol | Dexrazoxane may decrease the excretion rate of Pindolol which could result in a higher serum level. |
| Piperacillin | Piperacillin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Piracetam | Dexrazoxane may decrease the excretion rate of Piracetam which could result in a higher serum level. |
| Piretanide | Piretanide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. |
| Pirfenidone | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Pirfenidone. |
| Piroxicam | Piroxicam may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Pitolisant | Dexrazoxane may decrease the excretion rate of Pitolisant which could result in a higher serum level. |
| Plazomicin | Dexrazoxane may decrease the excretion rate of Plazomicin which could result in a higher serum level. |
| Plerixafor | Dexrazoxane may decrease the excretion rate of Plerixafor which could result in a higher serum level. |
| Polythiazide | Polythiazide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. |
| Pomalidomide | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Pomalidomide. |
| Ponatinib | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Ponatinib. |
| Ponesimod | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Ponesimod. |
| Potassium | Potassium may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. |
| Potassium acetate | Dexrazoxane may decrease the excretion rate of Potassium acetate which could result in a higher serum level. |
| Potassium bicarbonate | Dexrazoxane may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level. |
| Potassium cation | Potassium cation may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. |
| Potassium | Dexrazoxane may decrease the excretion rate of Potassium chloride which could result in a higher serum level. |
| Potassium citrate | Potassium citrate may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. |
| Potassium nitrate | Dexrazoxane may decrease the excretion rate of Potassium nitrate which could result in a higher serum level. |
| Potassium | Dexrazoxane may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level. |
| Potassium sulfate | Dexrazoxane may decrease the excretion rate of Potassium sulfate which could result in a higher serum level. |
| Pralatrexate | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Pralatrexate. |
| Pralidoxime | Dexrazoxane may decrease the excretion rate of Pralidoxime which could result in a higher serum level. |
| Pramipexole | Dexrazoxane may decrease the excretion rate of Pramipexole which could result in a higher serum level. |
| Prasugrel | The risk or severity of bleeding can be increased when Prasugrel is combined with Dexrazoxane. |
| Prednisolone | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Prednisolone. |
| Prednisone | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Prednisone. |
| Pregabalin | Pregabalin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Probenecid | Dexrazoxane may decrease the excretion rate of Probenecid which could result in a higher serum level. |
| Procainamide | Dexrazoxane may decrease the excretion rate of Procainamide which could result in a higher serum level. |
| Procaine | Dexrazoxane may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level. |
| Procarbazine | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Procarbazine. |
| Promethazine | Dexrazoxane may decrease the excretion rate of Promethazine which could result in a higher serum level. |
| Propantheline | Dexrazoxane may decrease the excretion rate of Propantheline which could result in a higher serum level. |
| Propiverine | Dexrazoxane may decrease the excretion rate of Propiverine which could result in a higher serum level. |
| Propranolol | Dexrazoxane may decrease the excretion rate of Propranolol which could result in a higher serum level. |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Propylthiouracil. |
| Protein C | The risk or severity of bleeding can be increased when Protein C is combined with Dexrazoxane. |
| Protein S human | The risk or severity of bleeding can be increased when Protein S human is combined with Dexrazoxane. |
| Prucalopride | Dexrazoxane may decrease the excretion rate of Prucalopride which could result in a higher serum level. |
| Pyrantel | Dexrazoxane may decrease the excretion rate of Pyrantel which could result in a higher serum level. |
| Pyrazinamide | Pyrazinamide may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Pyridoxine | Pyridoxine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Pyrithione | Dexrazoxane may decrease the excretion rate of Pyrithione which could result in a higher serum level. |
| Quetiapine | Dexrazoxane may decrease the excretion rate of Quetiapine which could result in a higher serum level. |
| Quinethazone | Quinethazone may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. |
| Quinidine | Dexrazoxane may decrease the excretion rate of Quinidine which could result in a higher serum level. |
| Rabeprazole | Dexrazoxane may decrease the excretion rate of Rabeprazole which could result in a higher serum level. |
| Rabies immune | The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Dexrazoxane. |
| Rabies antigen, A | The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Dexrazoxane. |
| Rabies antigen, B | The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Dexrazoxane. |
| Raltitrexed | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Dexrazoxane. |
| Ramelteon | Dexrazoxane may decrease the excretion rate of Ramelteon which could result in a higher serum level. |
| Ranitidine | Dexrazoxane may decrease the excretion rate of Ranitidine which could result in a higher serum level. |
| Ranolazine | Ranolazine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Rasagiline | Dexrazoxane may decrease the excretion rate of Rasagiline which could result in a higher serum level. |
| Ravulizumab | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Ravulizumab. |
| Reserpine | Reserpine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Resorcinol | Dexrazoxane may decrease the excretion rate of Resorcinol which could result in a higher serum level. |
| Reteplase | The risk or severity of bleeding can be increased when Reteplase is combined with Dexrazoxane. |
| Reviparin | The risk or severity of bleeding can be increased when Reviparin is combined with Dexrazoxane. |
| Ribavirin | Dexrazoxane may decrease the excretion rate of Ribavirin which could result in a higher serum level. |
| Ribostamycin | Dexrazoxane may decrease the excretion rate of Ribostamycin which could result in a higher serum level. |
| Rilonacept | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Rilonacept. |
| Risankizumab | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Risankizumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Dexrazoxane. |
| Rivaroxaban | Dexrazoxane may decrease the excretion rate of Rivaroxaban which could result in a higher serum level. |
| Rizatriptan | Dexrazoxane may decrease the excretion rate of Rizatriptan which could result in a higher serum level. |
| Rofecoxib | Rofecoxib may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Roflumilast | Roflumilast may increase the immunosuppressive activities of Dexrazoxane. |
| Ropeginterferon | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Ropeginterferon alfa-2b. |
| Ropivacaine | Ropivacaine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Rosiglitazone | Dexrazoxane may decrease the excretion rate of Rosiglitazone which could result in a higher serum level. |
| Rotavirus vaccine | The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Dexrazoxane. |
| Rubella virus vaccine | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Dexrazoxane. |
| Ruxolitinib | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Ruxolitinib. |
| Sacubitril | Dexrazoxane may decrease the excretion rate of Sacubitril which could result in a higher serum level. |
| Salbutamol | Dexrazoxane may decrease the excretion rate of Salbutamol which could result in a higher serum level. |
| Salicylamide | Salicylamide may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Salicylic acid | Salicylic acid may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Salmon calcitonin | Salmon calcitonin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Salsalate | Salsalate may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Sarilumab | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Sarilumab. |
| Satralizumab | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Satralizumab. |
| Saxagliptin | Dexrazoxane may decrease the excretion rate of Saxagliptin which could result in a higher serum level. |
| Secobarbital | Dexrazoxane may decrease the excretion rate of Secobarbital which could result in a higher serum level. |
| Secukinumab | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Secukinumab. |
| Selenious acid | Dexrazoxane may decrease the excretion rate of Selenious acid which could result in a higher serum level. |
| Selenium | Dexrazoxane may decrease the excretion rate of Selenium which could result in a higher serum level. |
| Sibutramine | Dexrazoxane may decrease the excretion rate of Sibutramine which could result in a higher serum level. |
| Siltuximab | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Siltuximab. |
| Siponimod | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Siponimod. |
| Sipuleucel-T | The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Dexrazoxane. |
| Sirolimus | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Sirolimus. |
| Sitagliptin | Dexrazoxane may decrease the excretion rate of Sitagliptin which could result in a higher serum level. |
| SVaccine, Live | The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Dexrazoxane. |
| Sodium acetate | Dexrazoxane may decrease the excretion rate of Sodium acetate which could result in a higher serum level. |
| Sodium | Dexrazoxane may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level. |
| Sodium citrate | The risk or severity of bleeding can be increased when Sodium citrate is combined with Dexrazoxane. |
| Sodium fluoride | Dexrazoxane may decrease the excretion rate of Sodium fluoride which could result in a higher serum level. |
| Sodium sulfate | Dexrazoxane may decrease the excretion rate of Sodium sulfate which could result in a higher serum level. |
| Sofosbuvir | Dexrazoxane may decrease the excretion rate of Sofosbuvir which could result in a higher serum level. |
| Solriamfetol | Dexrazoxane may decrease the excretion rate of Solriamfetol which could result in a higher serum level. |
| Sorafenib | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Sorafenib. |
| Sorbitol | Dexrazoxane may decrease the excretion rate of Sorbitol which could result in a higher serum level. |
| Spesolimab | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Spesolimab. |
| Spironolactone | Spironolactone may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. |
| Stiripentol | Dexrazoxane may decrease the excretion rate of Stiripentol which could result in a higher serum level. |
| Streptokinase | The risk or severity of bleeding can be increased when Streptokinase is combined with Dexrazoxane. |
| Streptomycin | Dexrazoxane may decrease the excretion rate of Streptomycin which could result in a higher serum level. |
| Streptozocin | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Streptozocin. |
| Strontium chloride | Dexrazoxane may decrease the excretion rate of Strontium chloride which could result in a higher serum level. |
| Sucralfate | Sucralfate may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Sulbactam | Dexrazoxane may decrease the excretion rate of Sulbactam which could result in a higher serum level. |
| Sulfadiazine | Sulfadiazine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Sulfamethoxazole | The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Dexrazoxane. |
| Sulfasalazine | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Sulfasalazine. |
| Sulfinpyrazone | The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Dexrazoxane. |
| Sulindac | Sulindac may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Sulodexide | The risk or severity of bleeding can be increased when Sulodexide is combined with Dexrazoxane. |
| Sumatriptan | Dexrazoxane may decrease the excretion rate of Sumatriptan which could result in a higher serum level. |
| Sunitinib | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Sunitinib. |
| S Estrogens, A | Dexrazoxane may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level. |
| S Estrogens, B | Dexrazoxane may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level. |
| Tacrolimus | Tacrolimus may increase the immunosuppressive activities of Dexrazoxane. |
| Tadalafil | Dexrazoxane may decrease the excretion rate of Tadalafil which could result in a higher serum level. |
| Tamsulosin | Dexrazoxane may decrease the excretion rate of Tamsulosin which could result in a higher serum level. |
| Teduglutide | Dexrazoxane may decrease the excretion rate of Teduglutide which could result in a higher serum level. |
| Tegafur | Dexrazoxane may decrease the excretion rate of Tegafur which could result in a higher serum level. |
| Telavancin | Dexrazoxane may decrease the excretion rate of Telavancin which could result in a higher serum level. |
| Temazepam | Temazepam may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Temozolomide | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Temozolomide. |
| Temsirolimus | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Temsirolimus. |
| Tenecteplase | The risk or severity of bleeding can be increased when Tenecteplase is combined with Dexrazoxane. |
| Teniposide | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Teniposide. |
| Tenofovir alafenamide | The serum concentration of Tenofovir alafenamide can be increased when it is combined with Dexrazoxane. |
| Tenofovir disoproxil | Tenofovir disoproxil may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Tenoxicam | Tenoxicam may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Teprotumumab | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Teprotumumab. |
| Terbutaline | Dexrazoxane may decrease the excretion rate of Terbutaline which could result in a higher serum level. |
| Teriflunomide | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Teriflunomide. |
| Testolactone | Dexrazoxane may decrease the excretion rate of Testolactone which could result in a higher serum level. |
| Testosterone | Dexrazoxane may decrease the excretion rate of Testosterone which could result in a higher serum level. |
| Testosterone | Dexrazoxane may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level. |
| Testosterone enan | Dexrazoxane may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level. |
| Testosterone propi | Dexrazoxane may decrease the excretion rate of Testosterone propionate which could result in a higher serum level. |
| Testosterone | Dexrazoxane may decrease the excretion rate of Testosterone undecanoate which could result in a higher serum level. |
| Tetracycline | Dexrazoxane may decrease the excretion rate of Tetracycline which could result in a higher serum level. |
| Tetradecyl | Dexrazoxane may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level. |
| Thalidomide | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Thalidomide. |
| Thiabendazole | Dexrazoxane may decrease the excretion rate of Thiabendazole which could result in a higher serum level. |
| Thiethylperazine | Thiethylperazine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Thiotepa | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Thiotepa. |
| Tiaprofenic acid | Tiaprofenic acid may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Ticagrelor | The risk or severity of bleeding can be increased when Ticagrelor is combined with Dexrazoxane. |
| borne encephalitis | The therapeutic efficacy of Tick-borne encephalitis vaccine (whole virus, inactivated) can be decreased when used in combination with Dexrazoxane. |
| Ticlopidine | The risk or severity of bleeding can be increased when Ticlopidine is combined with Dexrazoxane. |
| Tiludronic acid | Dexrazoxane may decrease the excretion rate of Tiludronic acid which could result in a higher serum level. |
| Timolol | Timolol may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Tinidazole | Dexrazoxane may decrease the excretion rate of Tinidazole which could result in a higher serum level. |
| Tinzaparin | The risk or severity of bleeding can be increased when Tinzaparin is combined with Dexrazoxane. |
| Tioguanine | The risk or severity of adverse effects can be increased when Tioguanine is combined with Dexrazoxane. |
| Tiopronin | Dexrazoxane may decrease the excretion rate of Tiopronin which could result in a higher serum level. |
| Tiotropium | Dexrazoxane may decrease the excretion rate of Tiotropium which could result in a higher serum level. |
| Tirofiban | The risk or severity of bleeding can be increased when Tirofiban is combined with Dexrazoxane. |
| Tixocortol | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Tixocortol. |
| Tobramycin | Dexrazoxane may decrease the excretion rate of Tobramycin which could result in a higher serum level. |
| Tocilizumab | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Tocilizumab. |
| Tocopherol | Dexrazoxane may decrease the excretion rate of Tocopherol which could result in a higher serum level. |
| Tofacitinib | Dexrazoxane may increase the immunosuppressive activities of Tofacitinib. |
| Tolazamide | Dexrazoxane may decrease the excretion rate of Tolazamide which could result in a higher serum level. |
| Tolbutamide | Dexrazoxane may decrease the excretion rate of Tolbutamide which could result in a higher serum level. |
| Tolcapone | Tolcapone may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Tolfenamic acid | Tolfenamic acid may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Tolmetin | Tolmetin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Tolterodine | Dexrazoxane may decrease the excretion rate of Tolterodine which could result in a higher serum level. |
| Tolvaptan | Tolvaptan may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. |
| Topiramate | Topiramate may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Topotecan | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Topotecan. |
| Torasemide | Torasemide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Dexrazoxane. |
| Trabectedin | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Trabectedin. |
| Tramadol | Tramadol may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Trametinib | Dexrazoxane may decrease the excretion rate of Trametinib which could result in a higher serum level. |
| Trastuzumab | Trastuzumab may increase the neutropenic activities of Dexrazoxane. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Trastuzumab emtansine. |
| Tretinoin | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Tretinoin. |
| Triamcinolone | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Triamcinolone. |
| Triamterene | Triamterene may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. |
| Triazolam | Dexrazoxane may decrease the excretion rate of Triazolam which could result in a higher serum level. |
| Trichlormethiazide | Trichlormethiazide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. |
| Triethylenetetramine | Dexrazoxane may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level. |
| Trifluridine | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Trifluridine. |
| Triflusal | The risk or severity of bleeding can be increased when Triflusal is combined with Dexrazoxane. |
| Trilostane | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Trilostane. |
| Trimebutine | Dexrazoxane may decrease the excretion rate of Trimebutine which could result in a higher serum level. |
| Trimethoprim | Dexrazoxane may decrease the excretion rate of Trimethoprim which could result in a higher serum level. |
| Trimetrexate | Dexrazoxane may decrease the excretion rate of Trimetrexate which could result in a higher serum level. |
| Tropisetron | Dexrazoxane may decrease the excretion rate of Tropisetron which could result in a higher serum level. |
| Typhoid vaccine | The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Dexrazoxane. |
| Typhoid Vaccine | The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Dexrazoxane. |
| Typhoid Vi | The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Dexrazoxane. |
| Upadacitinib | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Upadacitinib. |
| Urokinase | The risk or severity of bleeding can be increased when Urokinase is combined with Dexrazoxane. |
| Vaborbactam | Dexrazoxane may decrease the excretion rate of Vaborbactam which could result in a higher serum level. |
| Valaciclovir | Valaciclovir may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Valentine | Dexrazoxane may decrease the excretion rate of Valbenazine which could result in a higher serum level. |
| Valdecoxib | Valdecoxib may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Valganciclovir | Dexrazoxane may decrease the excretion rate of Valganciclovir which could result in a higher serum level. |
| Vancomycin | Dexrazoxane may decrease the excretion rate of Vancomycin which could result in a higher serum level. |
| Varenicline | Dexrazoxane may decrease the excretion rate of Varenicline which could result in a higher serum level. |
| Varicella vaccine | The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Dexrazoxane. |
| Varicella zoster | The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Dexrazoxane. |
| Vedolizumab | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Vedolizumab. |
| Venlafaxine | Venlafaxine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Verapamil | Dexrazoxane may decrease the excretion rate of Verapamil which could result in a higher serum level. |
| Vibrio cholerae | The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Dexrazoxane. |
| Vilanterol | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Vilanterol. |
| Viloxazine | Dexrazoxane may decrease the excretion rate of Viloxazine which could result in a higher serum level. |
| Vinblastine | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Vinblastine. |
| Vincristine | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Vincristine. |
Pregnancy and Lactation
FDA Pregnancy Risk Category: C
Pregnancy
The manufacturer makes no recommendation regarding use during pregnancy. This drug can cause fetal harm; if this drug is used during pregnancy, or the patient becomes pregnant, apprise them of the potential hazard to the fetus. Advise females of reproductive potential to use effective contraception during treatment and for 3 months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment and for 3 months after the last dose.
Lactation
No information is available on the use of dexrazoxane during breastfeeding. The manufacturer recommends that women not breastfeed during treatment and for 2 weeks following the final dose of dexrazoxane. However, because dexrazoxane is used with doxorubicin, the abstinence period might be longer, depending on the doxorubicin dose.
How should this medicine be used?
Dexrazoxane injection comes as a powder to be mixed with liquid and injected into a vein by a doctor or nurse in a hospital. When dexrazoxane injection is used to prevent heart damage caused by doxorubicin, it is given over 15 minutes just before each dose of doxorubicin. When dexrazoxane injection is used to prevent tissue damage after an anthracycline medication has leaked out of a vein, it is given over 1 to 2 hours once a day for 3 days. The first dose is given as soon as possible within the first 6 hours after the leak occurs, and the second and third doses are given about 24 and 48 hours after the first dose.
What special precautions should I follow?
Before receiving dexrazoxane injection,
- tell your doctor and pharmacist if you are allergic to dexrazoxane, any other medications, or any ingredients in dexrazoxane injection. Ask your pharmacist for a list of the ingredients.
- tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention dimethylsulfoxide (DMSO) topical products.
- tell your doctor if you have or have ever had heart, kidney, or liver disease.
- tell your doctor if you are pregnant, plan to become pregnant, or plan to father a child. You should not become pregnant while you are receiving dexrazoxane injections. If you are receiving a dexrazoxane injection (Zinecard), you should use birth control during your treatment. If you are receiving dexrazoxane injection (Totect), you should use birth control during your treatment and for at least 6 months after your final dose. If you are male, you and your female partner should use birth control during your treatment and for 3 months after you stop receiving dexrazoxane injections (Protect). Talk to your doctor about birth control methods that will work for you. If you or your partner become pregnant while receiving dexrazoxane injection, call your doctor. Dexrazoxane may harm the fetus.
- tell your doctor if you are breastfeeding. You should not breastfeed while you are receiving dexrazoxane (Zinecard) injections. If you are receiving dexrazoxane injection (Totect), you should not breastfeed while you are receiving treatment and for 2 weeks after your final dose.
- you should know that this medication may decrease fertility in men. Talk to your doctor about the risks of receiving dexrazoxane injections.
- if you are having surgery, including dental surgery, tell the doctor or dentist that you are receiving a dexrazoxane injection.
- you should know that treatment with dexrazoxane injection decreases but does not eliminate the risk that doxorubicin will damage your heart. Your doctor will still need to monitor you carefully to see how doxorubicin has affected your heart.
References
